ClinicalTrials.gg
CompletedNCT03463993Updated Jun 1, 2022Results posted

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

A Phase 3 interventional study of Tranexamic Acid and Oxytocin in Post Partum Hemorrhage, sponsored by University of Zimbabwe. Completed at 2 sites in Zimbabwe. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by University of Zimbabwe · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.

Enrollment
11th of 50
506 · median 198
Started
2018
with 10 others
Phase 3
16 of 50
3 open now
Registered
20th of 50
by date
Lead sponsor
2 of 50
University of Zimbabwe

Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 11th largest by enrollment, is one of 11 that started in 2018, is one of 16 in phase 3, and was the 20th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

Background Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide accounting for 25% of maternal deaths. In Zimbabwe PPH is the second most common cause of death. Tranexamic acid (TXA) is widely used to reduce blood loss in elective surgery, bleeding trauma patients, and menorrhagia.

The investigators seek to determine the efficacy of TXA in reducing PPH during and after elective caesarean section.

Methods and Design The investigators intend to perform an open label randomized control study of 1,162 women who are undergoing elective caesarean section. The participants will be randomly selected to receive an intravenous infusion of TXA 10 minutes prior to skin incision or not to receive the intervention. Prophylactic oxytocin will be administered to all the women.

The primary outcome will be incidence of PPH defined by blood loss equal to or more than 1,000ml calculated by determining the difference in haematocrit values taken prior to and 48 hours after caesarean section.

Discussion In addition to prophylactic uterotonic administration, TXA is a complementary component acting on the haemostatic process that can be used in the third stage of labour to prevent PPH. It is a promising intervention that is cheap, easy to administer and would be easy to add to routine delivery protocols in hospitals. It would also help to conserve precious resources by reducing the need for blood products, and expensive surgical interventions to manage PPH.

This large adequately powered randomized study seeks to determine the efficacy of TXA to validate its routine use at caesarean section to prevent PPH.

Read the detailed description

RESEARCH QUESTION Does intravenous Tranexamic Acid (TXA) 10mg/kg plus Oxytocin 5 International Units (IU) result in a lower incidence of primary postpartum haemorrhage compared to Oxytocin alone after elective caesarean section.

RATIONALE FOR THE RESEARCH Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide accounting for 25% of maternal deaths. In Zimbabwe, PPH is the second most common cause of death. Tranexamic acid (TXA) is widely used to reduce blood loss in elective surgery, bleeding trauma patients, and menorrhagia.

In addition to prophylactic uterotonic administration, TXA is a complementary component acting on the haemostatic process that can be used in the third stage of labour to prevent PPH. It is a promising intervention that is cheap, easy to administer and would be easy to add to routine delivery protocols in hospitals. It would also help to conserve precious resources by reducing the need for blood products, and expensive surgical interventions to manage PPH.

The investigators seek to determine the efficacy of TXA in reducing PPH during and after elective caesarean section.

RESEARCH OBJECTIVES

  1. To assess the impact of TXA (10mg/kg) given 10 minutes prior to elective caesarean section on postpartum blood loss
  2. To assess the potential adverse effects of TXA given 10 minutes prior to elective caesarean section Primary Outcome

    • Incidence of PPH defined by blood loss equal to or exceeding 1000ml following elective caesarean section Secondary Outcomes
    • Estimated blood loss during caesarean section
    • Need for blood transfusion
    • Use of additional uterotonics (such as oxytocin infusion or prostaglandins)
    • TXA side effects
    • Incidence of emergency surgery for PPH
    • Duration of mother's postnatal hospital stay
    • Neonatal outcome RESEARCH METHODOLOGY Research Design The aim of this study is to compare the effect of a low dose of TXA (10mg/kg) administered 10 minutes prior to elective caesarean section with prophylactic oxytocin administration, versus prophylactic oxytocin alone in an open label randomized clinical trial (RCT). An RCT is appropriate as it aims to reduce bias when testing this potentially new intervention.

Target Population Women undergoing elective caesarean sections at Harare and Parirenyatwa Hospitals based on set inclusion and exclusion criteria Inclusion criteria Pregnant woman with signed informed consent, who understand English and/or Shona, at estimated gestational age of 38 weeks or older, requiring Elective Caesarean Section, with a live intrauterine fetus.

Exclusion criteria Placental Abruption, emergency caesarean section, current or previous history of significant disease including heart disease, liver, renal disorders; known coagulopathy or history of deep venous thrombosis and/or pulmonary embolism, or arterial thrombosis (angina pectoris, myocardial infarction, stroke); history of epilepsy or seizures; autoimmune disease; sickle cell disease; severe haemorrhagic disease; intrauterine fetal demise; eclampsia/HELLP syndrome; administration of anticoagulants - clexane or antiplatelet agents in the week prior to delivery.

Sample Size A total sample size of 1,162 (581 per group) was calculated assuming a proportion of 2.1% PPH in the experimental group and 5.8% in the control group at 95% confidence interval and 90% power using Fleiss formula.

Subjects' state of physical health Healthy Intervention Participants receive either 10mg/kg of TXA 10 minutes prior to elective caesarean section with prophylactic oxytocin administration after delivery of the baby, versus prophylactic oxytocin alone after delivery of the baby.

Assessment Questionnaire (attached). Vital signs (heart rate, blood pressure, respiratory rate) noted before surgery, immediately after placental delivery, and 1 to 2 hours after birth Full blood count (FBC), Urea \& electrolytes (u\&e) and liver function tests (LFTs) performed a day before delivery (routinely performed) U\&e, LFTs and FBC assessed 48 hours after delivery. Estimated blood loss (EBL) using the difference in hematocrit values taken prior to and 48 hours after caesarean delivery.

The investigators will also note the standard EBL based on estimates made by the anaesthetist after assessment of patient's linen and abdominal swabs.

RISKS AND BENEFITS The common adverse effects include headaches (50.4 - 60.4%), backaches (20.7 - 31.4%), nasal sinus problem (25.4%), abdominal pain (12 - 19.8%), diarrhea (12.2%), fatigue (5.2%) and anaemia (5.6%).

The WOMAN Trial collaborators found that TXA actually reduces mortality due to bleeding in women with PPH with no adverse effects.

Tranexamic acid potentiates the blood clotting system and is used to treat and prevent bleeding. Use of TXA could potentially prevent PPH due to factors other than uterine atony, where uterotonics will not be effective.

COSTS AND COMPENSATION Study participants will not receive any compensation. The cost of TXA shall not be incurred by the study participants. They will bear their usual admission and caesarean section costs that they would otherwise have borne had they not participated in the study.

INFORMED CONSENT All subjects or legally authorized representatives for minors are expected to be give informed consent.

CONFIDENTIALITY ASSURANCES Information collected from the participants shall be confidential, will be assigned a code and no personal identifiers will be used. Information collected will be stored in a secure place only accessible to the researcher and assistants, as well as on a password-protected laptop computer. Consent forms will be kept for three years after the completion of the investigation unless stipulated otherwise by the Medical Research Council of Zimbabwe.

CONFLICTS OF INTERESTS The study is being carried out in partial fulfillment of the degree of Masters of Medicine in Obstetrics and Gynaecology. No other gains are to be obtained from carrying out the study.

COLLABORATIVE AGREEMENTS N/A INTENDED USE OF RESULTS The results of the study will be submitted to the College of Health Sciences as part of the requirements for completion of the degree of Masters of Medicine in Obstetrics and Gynaecology, and may be considered for publications to add to the current body of knowledge on the use of TXA.

03

Conditions studied

  • Post Partum Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant woman with signed ***
  • Understand English and/or Shona
  • Estimated gestational age of 38 weeks or older
  • Requiring Elective Caesarean Section defined as caesarean section performed before onset of labour
  • Live intrauterine fetus

    • The study will enrol participants who are Pregnant and who have a signed informed Consent form. Some of the pregnant women may be minors as they are occasionally included in patients planned for elective caesarean section for varying indications. Their inclusion also will make the results of the trial generalizable to elective caesarean section patients attended to at the two study hospitals. Consent will be sought from a legally authorized representative such as the parent or guardian.

Exclusion criteria

Exclusion Criteria:

  • Placental Abruption
  • Emergency caesarean section
  • Current or previous history of significant disease including heart disease, liver, renal disorders
  • Known coagulopathy or history of deep venous thrombosis and/or pulmonary embolism, or arterial thrombosis (angina pectoris, myocardial infarction, stroke)
  • History of epilepsy or seizures
  • disease
  • Sickle cell disease
  • Severe haemorrhagic disease
  • Intrauterine fetal demise
  • Eclampsia/HELLP syndrome
  • Administration of anticoagulants - clexane or antiplatelet agents in the week prior to delivery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    Group A

    Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.

    Drug: Tranexamic Acid · Drug: Oxytocin

  • Active comparator
    Group B

    Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby

    Drug: Oxytocin

Interventions

  • TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.

    Also known as: TXA

  • 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.

    Also known as: Prophylactic oxytocin

06

What researchers measure

Primary outcomes

  1. Number of Participants With Postpartum Haemorrhage (PPH)

    PPH based on Haematocrit calculation and PPH based on Haemoglobin calculation

    Time frame: Up to 48 hours post-caesarean section

Secondary outcomes

  1. Estimated Blood Loss

    Blood loss during caesarean section based on visual estimation and calculation.

    Time frame: At caesarean section

  2. Amount of Blood Transfused

    Requirement by participant of blood transfusion

    Time frame: At caesarean section up to 48 hours post-caesarean section

  3. Number of Participants With Use of Additional Uterotonics

    Number of participants who received additional uterotonics such as an oxytocin infusion or prostaglandin (misoprostol).

    Time frame: At caesarean section up to 48 hours post-caesarean section

  4. Number of Participants With Tranexamic Acid Side Effects

    Number of participants with adverse effects related to tranexamic acid use

    Time frame: From intravenous infusion of the drug up to 48 hours post-caesarean section

  5. Number of Participants Requiring Emergency Surgery for PPH

    Number of participants requiring emergency surgical procedures to manage any PPH that occurs

    Time frame: At caesarean section up to 48 hours post-caesarean section

  6. Number of Days of Participants' Hospital Stay

    The number of days the participant stayed in hospital from the date of admission to date of discharge from hospital.

    Time frame: From date of randomization until the day 2 post-caesarean section (date of discharge from hospital) or date of death whichever comes earlier

  7. Neonatal Outcome - Weight

    Neonatal birth weight in grams

    Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier

  8. Neonatal Outcome - APGAR Score of the Neonates at 1 Minute and 5 Minutes After Delivery

    APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scores out of 10 at 1 minute and 5 minutes. A measure of the physical condition of a newborn infant. It is obtained by adding points (maximum score of 2, 1, or 0 as minimum score) for Appearance (0 - blue/pale, 1 - pink body, blue extremities, 2 - pink); Pulse (0 - absent heart rate, 1 - below 100 beats per minute, 2 - over 100 beats per minute), Grimace (Reflex irritability - 0 - floppy, 1 - minimal response to stimulation, 2- prompt response to stimulation), Activity (muscle tone: 0 - absent, 1 - Flexed arms and legs, 2 - active), Respiration ( 0 - absent, 1 - slow or irregular, 2 - vigorous cry). APGAR score at 1minute or 5 minute can be a minimum of of 0 (0+0+0+0+0) or maximum of 10 (2 for each parameter above).

    Time frame: Scores at 1 minute from time of delivery and at 5 minutes after delivery

  9. Neonatal Outcome - Number of Neonates Admitted to the Neonatal Unit

    Number of neonates requiring admission to the neonatal unit from time of delivery at caesarean section

    Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier

  10. Neonatal Outcome - Number of Neonates Diagnosed With Jaundice

    Number of neonates with clinical jaundice (yellowing of the skin or whites of the eyes)

    Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier

  11. Neonatal Outcome - Thromboembolic Event

    Number of neonatal thromboembolic events

    Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier

  12. Neonatal Outcome - Death

    Neonatal death that occurs

    Time frame: From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier

07

Results

Posted Apr 20, 2022
Limitations and caveats
The a priori power was not been achieved as the target sample size had not yet been achieved due to reasons beyond the scope of the study. The study had no placebo and was not blinded.

Participant flow

From 8 April 2018 to 31 December 2018, we recruited 506 eligible patients. The trial was conducted at two tertiary institutions that are affiliated to the University of Zimbabwe. These serve as referral centres for 12 local authority clinics located in Harare as well as district and provincial hospitals in the surrounding provinces: Harare Central Hospital i.e. Harare Maternity Hospital (HMH) and Parirenyatwa Group of Hospitals i.e. Mbuya Nehanda Maternity Hospital (MNMH).

Participant flow — Overall Study
MilestoneGroup AGroup B
Started253253
Completed224227
Not completed2926
Withdrew: Lost to follow-up78
Withdrew: Withdrawal by subject20
Withdrew: Protocol violation41
Withdrew: Had a vaginal delivery prior to caesarean delivery911
Withdrew: Had emergency caesarean delivery prior to elective caesarean delivery76

Outcome measures

PrimaryNumber of Participants With Postpartum Haemorrhage (PPH)

PPH based on Haematocrit calculation and PPH based on Haemoglobin calculation

Time frame:
Up to 48 hours post-caesarean section
Reported as:
Count of participants · Participants
Number of Participants With Postpartum Haemorrhage (PPH)
ParticipantsGroup AGroup B
PPH based on Haematocrit calculation4854
PPH based on Haemoglobin calculation5671
Statistical analysis
  • Group A vs Group B · Chi-squared · p = 0.549 (The p-value above is the calculated P value based on hematocrit.)
  • Group A vs Group B · Chi-squared · p = 0.138 (This is the calculated p-value based on hemoglobin .)
SecondaryEstimated Blood Loss

Blood loss during caesarean section based on visual estimation and calculation.

Time frame:
At caesarean section
Reported as:
Mean · ml
Estimated Blood Loss
mlGroup AGroup B
Visually estimated blood loss483.73 ± 182.56479.61 ± 139.49
Haematocrit-based calculation of estimated blood loss650.06 ± 631.50653.05 ± 796.03
Haemoglobin-based calculation of estimated blood loss644.30 ± 692.27707.68 ± 948.01
Statistical analysis
  • Group A vs Group B · t-test, 2 sided · p = 0.789 (0.789 is the calculated p-value for visually estimated blood loss: Visually estimated blood loss (ml): Group A mean 483.73 (standard deviation182.56); Group B 479.61 (139.49); p-value 0.789)
  • Group A vs Group B · t-test, 2 sided · p = 0.968 (0.968 is the calculated p-value based on hematocrit. Hematocrit-based calculation of estimated blood loss(ml): Group A mean 650.06 (standard deviation 631.50); Group B 653.05 (796.03); p-value 0.968)
  • Group A vs Group B · t-test, 2 sided · p = 0.447 (Hemoglobin-based calculation of estimated blood loss(ml) mean(standard deviation): Group A 644.30 (692.27); Group B 707.68 (948.01); p-value 0.447)
SecondaryAmount of Blood Transfused

Requirement by participant of blood transfusion

Time frame:
At caesarean section up to 48 hours post-caesarean section
Reported as:
Median · units of blood given
Amount of Blood Transfused
units of blood givenGroup AGroup B
Amount of Blood Transfused1.5 (1 to 2)2.5 (2 to 3)
Statistical analysis
  • Group A vs Group B · Wilcoxon (Mann-Whitney) · p = <0.05
SecondaryNumber of Participants With Use of Additional Uterotonics

Number of participants who received additional uterotonics such as an oxytocin infusion or prostaglandin (misoprostol).

Time frame:
At caesarean section up to 48 hours post-caesarean section
Reported as:
Count of participants · Participants
Number of Participants With Use of Additional Uterotonics
ParticipantsGroup AGroup B
Number of Participants With Use of Additional Uterotonics3832
Statistical analysis
  • Group A vs Group B · Chi-squared · p = <0.05
SecondaryNumber of Participants With Tranexamic Acid Side Effects

Number of participants with adverse effects related to tranexamic acid use

Time frame:
From intravenous infusion of the drug up to 48 hours post-caesarean section
Reported as:
Count of participants · Participants
Number of Participants With Tranexamic Acid Side Effects
ParticipantsGroup AGroup B
Number of Participants With Tranexamic Acid Side Effects73
SecondaryNumber of Participants Requiring Emergency Surgery for PPH

Number of participants requiring emergency surgical procedures to manage any PPH that occurs

Time frame:
At caesarean section up to 48 hours post-caesarean section
Reported as:
Count of participants · Participants
Number of Participants Requiring Emergency Surgery for PPH
ParticipantsGroup AGroup B
Number of Participants Requiring Emergency Surgery for PPH02
SecondaryNumber of Days of Participants' Hospital Stay

The number of days the participant stayed in hospital from the date of admission to date of discharge from hospital.

Time frame:
From date of randomization until the day 2 post-caesarean section (date of discharge from hospital) or date of death whichever comes earlier
Reported as:
Median · days
Number of Days of Participants' Hospital Stay
daysGroup AGroup B
Number of Days of Participants' Hospital Stay5 (4 to 5)5 (4 to 5)
SecondaryNeonatal Outcome - Weight

Neonatal birth weight in grams

Time frame:
From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Reported as:
Mean · grams
Neonatal Outcome - Weight
gramsGroup AGroup B
Neonatal Outcome - Weight3087.85 ± 523.983109.98 ± 513.13
SecondaryNeonatal Outcome - APGAR Score of the Neonates at 1 Minute and 5 Minutes After Delivery

APGAR (Appearance, Pulse, Grimace, Activity, Respiration) scores out of 10 at 1 minute and 5 minutes. A measure of the physical condition of a newborn infant. It is obtained by adding points (maximum score of 2, 1, or 0 as minimum score) for Appearance (0 - blue/pale, 1 - pink body, blue extremities, 2 - pink); Pulse (0 - absent heart rate, 1 - below 100 beats per minute, 2 - over 100 beats per minute), Grimace (Reflex irritability - 0 - floppy, 1 - minimal response to stimulation, 2- prompt response to stimulation), Activity (muscle tone: 0 - absent, 1 - Flexed arms and legs, 2 - active), Respiration ( 0 - absent, 1 - slow or irregular, 2 - vigorous cry). APGAR score at 1minute or 5 minute can be a minimum of of 0 (0+0+0+0+0) or maximum of 10 (2 for each parameter above).

Time frame:
Scores at 1 minute from time of delivery and at 5 minutes after delivery
Reported as:
Median · units on a scale up to 10
Neonatal Outcome - APGAR Score of the Neonates at 1 Minute and 5 Minutes After Delivery
units on a scale up to 10Group AGroup B
Apgar score at 1 minute8 (8 to 9)9 (8 to 9)
Apgar score at 5 minutes9 (9 to 10)9 (9 to 10)
SecondaryNeonatal Outcome - Number of Neonates Admitted to the Neonatal Unit

Number of neonates requiring admission to the neonatal unit from time of delivery at caesarean section

Time frame:
From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Reported as:
Count of participants · Participants
Neonatal Outcome - Number of Neonates Admitted to the Neonatal Unit
ParticipantsGroup AGroup B
Neonatal Outcome - Number of Neonates Admitted to the Neonatal Unit3323
SecondaryNeonatal Outcome - Number of Neonates Diagnosed With Jaundice

Number of neonates with clinical jaundice (yellowing of the skin or whites of the eyes)

Time frame:
From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Reported as:
Count of participants · Participants
Neonatal Outcome - Number of Neonates Diagnosed With Jaundice
ParticipantsGroup AGroup B
Neonatal Outcome - Number of Neonates Diagnosed With Jaundice10
SecondaryNeonatal Outcome - Thromboembolic Event

Number of neonatal thromboembolic events

Time frame:
From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Reported as:
Count of participants · Participants
Neonatal Outcome - Thromboembolic Event
ParticipantsGroup AGroup B
Neonatal Outcome - Thromboembolic Event00
SecondaryNeonatal Outcome - Death

Neonatal death that occurs

Time frame:
From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
Reported as:
Count of participants · Participants
Neonatal Outcome - Death
ParticipantsGroup AGroup B
Neonatal Outcome - Death11

Adverse events

Collected over Adverse event data was collected up to the time the patient and baby were discharged from hospital which on average is on the third day post-caesarean section.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A0/224 (0%)0/224 (0%)7/224 (3.1%)
Group B0/227 (0%)0/227 (0%)3/227 (1.3%)
Most frequent other events
Most frequent other events
EventGroup AGroup B
HypotensionCardiac disorders3/2241/227
NauseaGastrointestinal disorders2/2240/227
HeadacheNervous system disorders1/2241/227
VomitingGastrointestinal disorders1/2241/227

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Mean29.5 ± 6.029.7 ± 6.529.6 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female224227451
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group AGroup BTotal
Black African224227451
Region of Enrollment
Region of Enrollment(participants)Group AGroup BTotal
Zimbabwe224227451
Gestational age
Gestational age(Weeks)Group AGroup BTotal
Median39 (38 to 40)39 (38 to 40)39 (38 to 40)
HIV status
HIV status(Participants)Group AGroup BTotal
Positive273562
Negative186187373
Unknown11516
Multiple pregnancy
Multiple pregnancy(Participants)Group AGroup BTotal
Count of participants6612
Placenta praevia
Placenta praevia(Participants)Group AGroup BTotal
Count of participants516

10 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Harare Central Hospital
    Harare, Zimbabwe
  • Parirenyatwa Group of Hospitals
    Harare, Zimbabwe
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — It is undecided whether the IPD will be made available to other researchers. Clearance is required first from ethical bodies and supervisors

Supporting information: Study protocol, Statistical analysis plan

Time frame: TBA

Access criteria: Communicate with researcher on chipo.gwanzura@gmail.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Dec 2018, 8 months.

Results were first posted in Apr 2022, 3 years 3 months after primary completion.

Of 20 phase 3 interventional studies under Postpartum Hemorrhage, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2018
First posted
Mar 13, 2018
StartActual
Apr 8, 2018
Primary completionActual
Dec 31, 2018
CompletionActual
Jun 30, 2019
Results first posted
Apr 20, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03463993
Lead sponsor
University of Zimbabwe
Responsible party
Chipo Gwanzura, MD (Junior Registrar, University of Zimbabwe) — Principal investigator
First posted
Mar 13, 2018
Start date
Apr 8, 2018
Primary completion
Dec 31, 2018
Completion
Jun 30, 2019
Results posted
Apr 20, 2022
Last update
Jun 1, 2022

Study contacts

Tsungai Chipato, MBChB FRCOG
study chair · Professor of Obstetrics and Gynaecology
Taazadza Nhemachena, MBChB MMED
study chair · Lecturer and Consultant
Chipo Gwanzura, MBChB
principal investigator · Registrar

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion